• 四川大學(xué)華西醫(yī)院老年科（成都，610041）;

【摘要】　目的　 應(yīng)用調(diào)查問(wèn)卷分析培訓(xùn)前后成都市社區(qū)醫(yī)生對(duì)肺炎球菌疫苗的認(rèn)識(shí)，為推動(dòng)社區(qū)肺炎球菌疫苗接種奠定基礎(chǔ)。　方法　 對(duì)215名成都市社區(qū)醫(yī)生進(jìn)行肺炎球菌疾病及預(yù)防知識(shí)的培訓(xùn)，并在培訓(xùn)前后行問(wèn)卷調(diào)查，回收問(wèn)卷并分析。　結(jié)果　 經(jīng)培訓(xùn)，社區(qū)醫(yī)生提高了對(duì)肺炎球菌疾病及疫苗接種知識(shí)的掌握程度，加深了對(duì)肺炎球菌疾病及疫苗接種重要性的認(rèn)識(shí)。　結(jié)論　 對(duì)社區(qū)醫(yī)生進(jìn)行肺炎球菌相關(guān)知識(shí)的培訓(xùn)，有利于提高社區(qū)醫(yī)生對(duì)肺炎球菌疫苗接種推薦的專(zhuān)業(yè)性和成功率。
【Abstract】　Objective　 To know the community doctors’ understanding of pneumococcal vaccine before and after the education via questionnaire. 　Methods　 A total of 215 community doctors in Chengdu were educated in pneumococcal disease and the prevention knowledge. Questionnaire investigation was performed before and after the education and the results were analyzed.　Results　 After the education, the acknowledgement of pneumococcal vaccination of the community doctors was improved.　Conclusion　 The education of the knowledge of pneumococcal vaccine for the community doctors helps to improve the acknowledgement of pneumococcal vaccination.

引用本文： 李峻,董碧蓉,舒德芬. 培訓(xùn)前后社區(qū)醫(yī)生對(duì)肺炎球菌疫苗認(rèn)識(shí)的調(diào)查分析. 華西醫(yī)學(xué), 2011, 26(1): 38-40. doi: 復(fù)制

1. 　Cripps AW, Leach AJ, Lehmann D. Pneumococcal vaccination in developing countries[J]. Lancet, 2006, 19, 368(9536): 644.
2. 　Butler JC, Breiman RF, Campbell JF, et al. Pneumococcal polysaccharide vaccine efficacy: an evaluation of current recommendations[J]. JAMA, 1993, 270(15): 1826-1831.
3. 　WHO position paper. 23-valent pneumococcal polysaccharide vaccine[J]. Wkly Epidemiol Rec, 2007, 82(12): 93-104.
4. 　WHO position paper. 23-valent pneumococcal polysaccharide vaccine[J]. Wkly Epidemiol Rec, 2008, 83(42): 373-384.
5. 　Christenson B, Hedlund J, Lunbergh P, et al. Additive preventive effect of influenza and pneumococcal vaccines in elderly persons[J]. Eur Respir J, 2004, 23(3): 363-368.
6. 　Christenson B, Pauksen K, Sylvan SP. Effect of influenza and pneumococcal vaccines in elderly persons in years of low influenza activity[J]. Virol J, 2008, 5: 52.
7. 　徐英, 董碧蓉. 23價(jià)肺炎球菌多糖疫苗預(yù)防老年人下呼吸道感染的效果考察[J]. 中國(guó)計(jì)劃免疫, 2005, 11(4): 287-291.
8. 　Cutts FT, Zaman SM, Enwere G, et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial[J]. Lancet, 2005, 365(9465): 1139-1146.
9. 　Klugman KP, Madhi SA, Huebner RE, et al. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection[J]. N Engl J Med, 2003, 349(14): 1341-1348.
10. 　Christenson B, Lundbergh P, Hedlund J, et al. Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in adults aged 65 years or older: a prospective study[J]. Lancet, 2001, 357(9261): 1008-1011.
11. 　WHO position paper. Pneumococcal vaccines[J]. Wkly Epidemiol Rec, 2003, 79(14): 110-119.
12. 　Nichol KL, Zimmerman R. Generalist and subspecialist physicians’ knowledge, attitudes and practices regarding influenza and pneumococcal vaccinations for elderly and other high-risk patients[J]. Arch Intern Med, 2001, 161 (22): 270-272.
13. 　徐英, 董碧蓉. 老年人群接種多價(jià)肺炎球菌疫苗的臨床免疫效果與經(jīng)濟(jì)效益[J]. 華西醫(yī)學(xué), 2003, 18(3): 442.
  1. 1. 　Cripps AW, Leach AJ, Lehmann D. Pneumococcal vaccination in developing countries[J]. Lancet, 2006, 19, 368(9536): 644.
  2. 2. 　Butler JC, Breiman RF, Campbell JF, et al. Pneumococcal polysaccharide vaccine efficacy: an evaluation of current recommendations[J]. JAMA, 1993, 270(15): 1826-1831.
  3. 3. 　WHO position paper. 23-valent pneumococcal polysaccharide vaccine[J]. Wkly Epidemiol Rec, 2007, 82(12): 93-104.
  4. 4. 　WHO position paper. 23-valent pneumococcal polysaccharide vaccine[J]. Wkly Epidemiol Rec, 2008, 83(42): 373-384.
  5. 5. 　Christenson B, Hedlund J, Lunbergh P, et al. Additive preventive effect of influenza and pneumococcal vaccines in elderly persons[J]. Eur Respir J, 2004, 23(3): 363-368.
  6. 6. 　Christenson B, Pauksen K, Sylvan SP. Effect of influenza and pneumococcal vaccines in elderly persons in years of low influenza activity[J]. Virol J, 2008, 5: 52.
  7. 7. 　徐英, 董碧蓉. 23價(jià)肺炎球菌多糖疫苗預(yù)防老年人下呼吸道感染的效果考察[J]. 中國(guó)計(jì)劃免疫, 2005, 11(4): 287-291.
  8. 8. 　Cutts FT, Zaman SM, Enwere G, et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial[J]. Lancet, 2005, 365(9465): 1139-1146.
  9. 9. 　Klugman KP, Madhi SA, Huebner RE, et al. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection[J]. N Engl J Med, 2003, 349(14): 1341-1348.
  10. 10. 　Christenson B, Lundbergh P, Hedlund J, et al. Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in adults aged 65 years or older: a prospective study[J]. Lancet, 2001, 357(9261): 1008-1011.
  11. 11. 　WHO position paper. Pneumococcal vaccines[J]. Wkly Epidemiol Rec, 2003, 79(14): 110-119.
  12. 12. 　Nichol KL, Zimmerman R. Generalist and subspecialist physicians’ knowledge, attitudes and practices regarding influenza and pneumococcal vaccinations for elderly and other high-risk patients[J]. Arch Intern Med, 2001, 161 (22): 270-272.
  13. 13. 　徐英, 董碧蓉. 老年人群接種多價(jià)肺炎球菌疫苗的臨床免疫效果與經(jīng)濟(jì)效益[J]. 華西醫(yī)學(xué), 2003, 18(3): 442.